Abstract
IntroductionLinaclotide, a minimally absorbed guanylate cyclase-C agonist, was evaluated in a Phase 3 trial. To fulfil EMA submission requirements, the efficacy, safety and effects of withdrawal of linaclotide 290 μg...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have